Canaccord raised the firm’s price target on Boston Scientific (BSX) to $117 from $101 and keeps a Buy rating on the shares. The firm said they reported solid Q4 results capping off a spectacular year of growth for the Med-Tech strategic. Given the scarcity of strategics with this sort of momentum, Canaccord thinks they likely could weather the optics of deceleration – especially if the company continues to augment growth with the heightened level of M&A occurring in the Med-Tech space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $122 from $107 at Citi
- Boston Scientific Reports Strong 2024 Financial Growth
- Boston Scientific Shines with Strong Earnings Performance
- Boston Scientific price target raised to $115 from $110 at BofA
- Boston Scientific reports Q4 adjusted EPS 70c, consensus 66c